Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AlphaRx, Inc.
Approval granted to begin phase II trial for Indaflex
August 10th, 2005
AlphaRx, Inc., (ALRX.OB) has received approval from the Therapeutic Products Directorate, Health Canada for the initiation of a phase II human trial for its lead pharmaceutical product Indaflex, a topical Indomethacin drug expected to treat patients suffering from osteoarthritis of the knee. The phase II clinical trial has been designed as a randomized, multicenter, doubleblind, placebo and vehicle-controlled trial. "The study will evaluate the efficacy and safety of 2.5% Indomethacin cream, Indaflex, in patients suffering from osteoarthritis of the knee," said Michael Lee, president of AlphaRx. "A total of 210 patients will be randomly divided into three arms of equal...
Source: Biotech Week (2005-08-10)
|
